| Gorman's Medical Services, Llc | |
|
1100 Dekalb Plaza Blvd Sw Fort Payne AL 35967-4868 | |
| (256) 845-0428 | |
| (256) 845-0428 |
| Full Name | Gorman's Medical Services, Llc |
|---|---|
| Speciality | General Practice |
| Location | 1100 Dekalb Plaza Blvd Sw, Fort Payne, Alabama |
| Authorized Official Name and Position | Joleen J Gorman (MEMBER) |
| Authorized Official Contact | 2568450428 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Gorman's Medical Services, Llc 1100 Dekalb Plaza Blvd Sw Fort Payne AL 35967-4868 Ph: (256) 845-0428 | Gorman's Medical Services, Llc 1100 Dekalb Plaza Blvd Sw Fort Payne AL 35967-4868 Ph: (256) 845-0428 |
| NPI Number | 1376870741 |
|---|---|
| Provider Enumeration Date | 11/05/2009 |
| Last Update Date | 09/23/2013 |
| Medicare PECOS PAC ID | 0941344063 |
|---|---|
| Medicare Enrollment ID | O20100212000426 |
News Archive
CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced that it will host the next installment of its popular STREAK program, to be held Thursday, Oct. 8 from 3 p.m. to 5 p.m.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.
Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application, "Methods and Compositions for the Treatment of Neurological Disease," which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain's temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).
Mylan Laboratories has announced that the U.S. Food and Drug Administration (FDA) has confirmed Mylan's current status as the only approved ANDA for all strengths of Amlodipine Besylate Tablets.
Three new articles present trends in survival for patients with ovarian, colon, and breast cancer in the United States by race and stage. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings reveal large, consistent, and persistent racial disparities in survival.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376870741 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 14962 (Alabama) | Primary |
| Provider Name | Joleen W Gorman |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1245278100 PECOS PAC ID: 1658382957 Enrollment ID: I20090727000156 |
News Archive
CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced that it will host the next installment of its popular STREAK program, to be held Thursday, Oct. 8 from 3 p.m. to 5 p.m.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.
Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application, "Methods and Compositions for the Treatment of Neurological Disease," which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain's temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).
Mylan Laboratories has announced that the U.S. Food and Drug Administration (FDA) has confirmed Mylan's current status as the only approved ANDA for all strengths of Amlodipine Besylate Tablets.
Three new articles present trends in survival for patients with ovarian, colon, and breast cancer in the United States by race and stage. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings reveal large, consistent, and persistent racial disparities in survival.
› Verified 3 days ago
News Archive
CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced that it will host the next installment of its popular STREAK program, to be held Thursday, Oct. 8 from 3 p.m. to 5 p.m.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.
Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application, "Methods and Compositions for the Treatment of Neurological Disease," which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain's temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).
Mylan Laboratories has announced that the U.S. Food and Drug Administration (FDA) has confirmed Mylan's current status as the only approved ANDA for all strengths of Amlodipine Besylate Tablets.
Three new articles present trends in survival for patients with ovarian, colon, and breast cancer in the United States by race and stage. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings reveal large, consistent, and persistent racial disparities in survival.
› Verified 3 days ago
C & H Discount Drugs Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1916 Gault Ave N, Fort Payne, AL 35967 Phone: 256-845-2004 Fax: 256-845-7839 | |
Hh Health System - Dekalb Rhc, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 415 Medical Center Dr Sw, Fort Payne, AL 35968 Phone: 256-997-2145 Fax: 256-997-2512 | |
Rainsville Family Practice Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 421 Medical Center Dr Sw, Fort Payne, AL 35968 Phone: 256-845-1401 Fax: 256-845-1402 | |
Dekalb Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 415 Medical Center Dr Sw, Fort Payne, AL 35968 Phone: 256-997-2820 Fax: 256-997-2890 | |
Northside Medical, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 211 Greenhill Blvd Nw, Fort Payne, AL 35967 Phone: 256-845-9355 | |
Doctors Med Care Of Fort Payne, P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1040 Glenn Blvd Sw, Fort Payne, AL 35967 Phone: 256-845-6900 Fax: 256-845-6905 | |
Truecare Medical Clinic, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 613 Gault Ave S, Fort Payne, AL 35967 Phone: 256-364-8875 Fax: 256-364-8875 |